Kornimate/medical-research-clean huggingface dataset:
risk-guided disease management plan to prevent heart failure in patients treated with previous chemotherapy (redeem)

Conditions: Heart Failure

Summary: this is a prospective study in which a process of identifying and reducing heart failure (hf) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago. the overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.

participants enrolled in this study will be randomized to cardio-oncology disease management plan ( co-dmp) that involves the use of surveillance imaging to detect subclinical left ventricular dysfunction (lvd), clinical review to ensure optimal risk factor control and cardio-protection and exercise/sedentariness intervention. the intervention will be delivered over a period of 6 months. usual care patients will then cross over the co-dmp for 6 months. the outcome from this study will show that subclinical lvd is more common among long term cancer survivors, and a co-dmp is feasible in reducing hf risk factors in this sub group of survivors.

Eligibility criteria:
inclusion criteria: 1. history of cancer \> 10 years ago 2. have received potentially toxic chemotherapy anthracycline (any dose) trastuzumab (herceptin) in breast-cancer with the her2 mutation or tyrosine kinase inhibitors (e.g. sunitinib) or left chest radiotherapy exclusion criteria: 1. ejection fraction at baseline echo \<50% 2. valvular stenosis or regurgitation of \>moderate severity 3. history of previous heart failure (baseline new york heart association (nyha) classification \>2) 4. systolic bp \<110 mmhg 5. pulse \<60/minute if not on beta blocker 6. inability to acquire interpretable images (identified from baseline echo) 7. contraindications to beta blockers or angiotensin-converting enzyme inhibitors 8. oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the chief investigators) that it is not appropriate for the patient to participate in this trial 9. already taking both angiotensin converting enzyme inhibitors/angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both. 10. unable to provide written informed consent to participate in this study
a pharmacokinetics and safety study of nemolizumab in adolescent participants with atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: the purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with ad.


Eligibility criteria:
key inclusion criteria * male or female participants ≥ 12 to \< 17 years of age * chronic ad that has been documented for at least 2 years * eczema area and severity index (easi) score ≥ 16 * investigator's global assessment (iga) score ≥ 3 * ad involvement ≥ 10% of body surface area (bsa) * documented recent history of inadequate response to topical medications * women of childbearing potential must agree to be strictly abstinent or to use an effective and approved method of contraception throughout the study and for 12 weeks after the last study drug injection. key exclusion criteria * body weight \< 30 kilogram (kg) * cutaneous infection within 1 week or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week * history of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example., monoclonal antibody) * any medical or psychological condition, or any clinically relevant laboratory abnormalities that may have put the subject at significant risk according to the investigator's judgment

Keywords: nemolizumab atopic dermatitis
randomized control trials of surgery for pediatric osa

Conditions: Sleep Apnea, Obstructive; Otorhinolaryngologic Diseases; Pediatric Disorder

Summary: randomized study on pediatric osa with 2 groups: mild-moderate osa and severe osa. mild-moderate are randomized to either expectancy or ate. severe are randomized to either ate or app. pediatric age span of 2 until 4,9 years.

children who are referred to ent clinic because of sleep-disordered breathing and fulfil the inclusion criteria undergo polysomnography (psg) and fill in questionnaires. depending on the outcome of the psg, whether a) the child have mild to moderate osa (ahi between 2-9.9) the family is asked to be in the study. if yes, the doctor take a sealed envelope and open it, either the child are randomized to adenotonsillectomy (ate) or 6 months expectancy. whether psg shows b) severe osa and the family accept participation the child is operated within a month. there is a straification beetween 2 groups, if ahi is 1) between 10 and 29.9 or 2) above 30. a sealed envelope is open in the operating room by the surgeon. the child is randomized to either ate or ate and suturing of the tonsillar pillars. the study is blinded for the family, who will not know which method the child has undergone. after 6 months all children will undergo follow-up with psg and questionnaires. if the expectancy group will deteriorate during waiting time, or the child still has moderate to severe osa, they will undergo ate. further follow-ups at three and ten years. altogether 160 children should be evaluated with two psg, 80 in each group.

Eligibility criteria:
inclusion criteria: * oahi \>= 2 * tonsillary hypertrophy, brodsky size 2-4 * adequate swedish knowledge exclusion criteria: * cardiovascular disorders * pulmonary disorders * neuromuscular disorders * cranoifacial malformations * genetic disorders * earlier performed adenoid-tonsillary-surgery * bleeding disorders

Keywords: tonsillectomy adenoidectomy adenoidpharyngoplasty osa
comparison of vasopressor boluses for management of hypotension after spinal anesthesia

Conditions: Cesarean Section Complications; Spinal Anesthetic Toxicity

Summary: in this study the investigators will compare the efficacy and side effects of two doses of norepinephrine bolus (6 mcg and 10 mcg) in management of maternal hypotensive episode after subarachnoid block during cesarean delivery.

maternal hypotension after subarachnoid block is a frequent and deleterious complication during cesarean delivery. although prophylaxis against hypotension using vasopressors had become a standard recommendation; the incidence of hypotension is still ∼ 20% . thus; management of maternal hypotension using vasopressor boluses is usually needed . the commonly used vasopressors during cesarean delivery are ephedrine, phenylephrine, and recently norepinephrine. the use of ephedrine is usually accompanied with maternal tachycardia and fetal acidosis. phenylephrine had been the first line for prevention and management of maternal hypotension; however, its use might result in bradycardia and decreased maternal cardiac output . norepinephrine is an alpha adrenergic agonist with weak beta adrenergic agonistic activity; thus, it does not cause significant cardiac depression as phenylephrine does. norepinephrine was introduced for use during cesarean delivery with promising results . few previous studies investigated the efficacy of norepinephrine infusion for prevention of maternal hypotension. a dose-response study had investigated the best dose of norepinephrine for prevention of maternal hypotension. in the aforementioned dose-response study, a dose of 6 mcg was reported as the best dose for prophylaxis against maternal hypotension. no studies had investigated the best bolus dose of norepinephrine for management of a maternal hypotensive episode. in this study the investigators will investigate the efficacy and side effects of two doses of norepinephrine bolus doses (6 mcg and 10 mcg) in management of maternal hypotensive episode after subarachnoid block during cesarean delivery.

Eligibility criteria:
inclusion criteria: * pregnant women * scheduled for cesarean delivery exclusion criteria: * patients with severe cardiac dysfunction * patients with low blood pressure * patients with ante-partum bleeding
dbs frequency on swallowing function in parkinson's disease

Conditions: Parkinson's Disease

Summary: the stimulation frequency has been found to affect the axial symptoms of freezing of gait (fog) and speech in advanced parkinson's disease (pd) patients with subthalamic nucleus deep brain stimulation (stn dbs), with the traditionally high stimulation frequency of 130 hz worsening while low frequency of 60 hz improving these symptoms. the effect of stimulation frequency on another important axial symptom, swallowing dysfunction, has not been studied. the investigators hypothesize that stimulation frequency could have similar effect on swallowing function.

this is the first study on the effect of the stimulation frequency on swallowing function in pd patients with stn dbs. swallowing dysfunction is often difficult to treat pharmacologically and associated with increased morbidity and mortality. this study hence would have significant clinical implications in the management of swallowing dysfunction in these pd patients with stn dbs and could potentially decrease their morbidity and mortality. the investigators expect that the traditionally high frequency stimulation of 130 hz would worsen while the low frequency stimulation of 60 hz would improve the swallowing function in opms summary

Eligibility criteria:
inclusion criteria: * eight pd patients with stn dbs and freezing of gait responsive to stimulation frequency changes will be enrolled. exclusion criteria: * patients who do not meet the inclusion criteria
the long-term effect on intestinal absorption and safety of treatment with glepaglutide in patients with short bowel syndrome

Conditions: Short Bowel Syndrome

Summary: the purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with short bowel syndrome (sbs). the trial will also investigate whether glepaglutide is safe during long-term use. all participants in the trial will receive glepaglutide injections. participants will have 14 visits with the study doctor. at 2 of these, participants will spend 48 hours at the trial site, one visit at the start of the trial and one after 24 weeks of treatment with glepaglutide. at all visits, participants will meet with trial staff and will have blood tests along with other clinical checks and tests done. participants will be asked about their health and medical history.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * age greater than or equal to 18 years and less than or equal to 90 years at screening * stable condition of sbs either with intestinal failure (sbs-if) or intestinal insufficiency. for patients with sbs-if, a stable condition is defined as less than 25 percent change in parenteral support (ps) volume or energy content for 4 weeks prior to screening. * stable body weight (less than 5 percent change in weight in the 3 months prior to screening) * wet weight of fecal excretion greater than or equal to 1500 grams per day demonstrated during a hospital stay prior to screening exclusion criteria: * more than 2 sbs-related or ps-related hospitalizations (e.g., catheter-related bacteremia/sepsis, bowel obstruction, severe water-electrolytes disturbances, etc.) within 6 months prior to screening * poorly controlled inflammatory bowel disease (ibd) that is moderately or severely active or fistula interfering with measurements or examinations required in the trial * current bowel obstruction * known radiation enteritis or significant villous atrophy, e.g., due to active celiac disease * cardiac disease defined as: decompensated heart failure (new york heart association \[nyha\] class iii-iv), unstable angina pectoris, and/or myocardial infarction within the last 6 months prior to screening * any history of colon cancer. history of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free state for at least 5 years * use of glucagon-like peptide-1 (glp-1), glp-2, human growth hormone (hgh), somatostatin, or analogs thereof, within 3 months prior to screening
photoplethysmography for diagnose incipient hypovolemia

Conditions: Hypovolemia

Summary: hypovolemia caused by acute bleeding increased morbi-mortality in emergency and operatin rooms. precise real-time diagnosis of incipient acute hypovolemia is lacking at the bedside. we hypothesize that the infrared-red signals of pulse oximetry are sensitive to acute changes in patient's volemia. we aimed to test this hypothesis in a cohort of healthy blood donors as a model of simulated acute hypovolemia.

this is a prospective and observational study designed to determine if the changes observed in finger photoplethysmographic waveform can detect incipient hypovolemia. the investigators will studied 60 blood donor volunteers as a model of slight hypovolemia (8-10% of the volemia). vital signs and photoplethysmography will be recorded in the thumb of the tested hand during a standard blood donation protocol. recorded data will be analyzed and compared before and after blood donation .

Eligibility criteria:
inclusion criteria: * written inform consent * weight \> 50 kg, * hemoglobin \>12.5 gr/dl exclusion criteria: * pregnancy, * ≤ 12 months from delivery or abortion, * symptoms of allergy, * fever \>37 °c, * infectious diseases, * addictions, * volunteers that received previous blood transfusions

Keywords: photoplethysmography vital signs hemodynamics
bullet: bladder ultrasound limits length (of time), expedites treatment

Conditions: Point-of-Care Bladder Ultrasound; Urethral Catheter

Summary: in this study patients presenting to the pediatric er with abdominal or pelvic complaints will be randomized to urethral bladder catheter or bladder ultrasound to compare time to completion of successful pelvic ultrasound, as determined by full visualization of uterus and ovaries.

in this study, we will enroll female pediatric emergency department (ed) patients presenting with a diagnosis of abdominal pain who may have a transabdominal pelvic ultrasound ordered by their treating physician (or nurse practitioner). in order to maximize the visualization of organs deep within the pelvis such as the ovaries and uterus, the patient's bladder must be full. the current practice at our institution, as well as numerous others, is to have a bladder catheter placed immediately when a transabdominal pelvic ultrasound is ordered, and then to fill the bladder in a retrograde manner in order to provide enhanced visualization of the pelvic structures. the process of inserting a bladder catheter into a pediatric patient is an invasive procedure which can be traumatic and painful to the patient. additionally, if the patient's bladder is already full, this procedure may be unnecessary. in this study, a point-of-care bladder ultrasound will be performed, upon enrollment of a patient by a study bedside sonographer (our pediatric emergency department nurse practitioners), to assess degree of bladder fullness. this measurement will then be repeated serially while the patient is receiving hydration and the ultrasound will be performed when the bladder is full. we hypothesize that this work flow will result in an equivalent time to transabdominal pelvic ultrasound completion and will reduce the number of potentially traumatic and painful, invasive urethral bladder catheterizations.

Eligibility criteria:
inclusion criteria: * age 8yr-18yrs * female * likely to have order placed for transabdominal pelvic ultrasound/ovarian ultrasound * no history of pelvic or bladder reconstructive surgery exclusion criteria: * pregnancy (known) * critically ill patients * patients with known renal or genitourinary structural abnormalities or prior pelvic/genitourinary surgery * chronic renal disease * patients presenting outside the defined treatment windows

Keywords: ovarian torsion point-of-care pelvic pain bedside ultrasound
protein profile of immunoregulatory factors in diabetic cataract

Conditions: Cataract; Type 2 Diabetes Mellitus

Summary: the purpose of this study is to compare the levels of several immunoregulatory factors in serums and aqueous humor of type ii diabetes cataract patients with those in senile non-diabetic cataract patients since disturbed cytokine and growth factor microenvironment in diabetic eye may contribute to an increased frequency of intraoperative and postoperative intraocular lens surgery complications.

the study compared the levels of several immunoregulatory molecules (vascular endothelial growth factor (vegf), monocyte chemotactic protein-1 (mcp-1), fas ligand (fasl), interleukin-10 (il-10) and interleukin-17 (il-17)) in serum and aqueous humor between type 2 diabetes mellitus patients, without clinically evident diabetic retinopathy or diabetic macular edema, and nondiabetic cataract patients. investigators also investigated whether concentrations of immunoregulatory molecules significantly correlated with intraoperative and postoperative parameters. particularly, investigators focused on the development of corneal edema as one of the main causes of low visual acuity in the immediate postoperative period after intraocular lens implantation. since disturbed cytokine and growth factor microenvironment in diabetic eye may contribute to an increased frequency of intraoperative and postoperative intraocular lens (iol) surgery complications, the findings may be relevant for the development of therapeutic strategies aimed to restore protein profile of immunoregulatory factors in parallel to cataract treatment.

Eligibility criteria:
inclusion criteria: * patients undergoing phacoemulsification combined with iol implantation * for diabetic group: duration of type 2 diabetes mellitus (t2dm) for 10 to 15 years * for diabetic group: therapy with oral hypoglycemic agents for glycemic control * no other ocular (retinal) or systemic diabetic complications of t2dm exclusion criteria: * patients who had cataract that could result from some other ocular condition, systemic disease (except t2dm for diabetic group) or trauma * patients with immune disease, local or systemic inflammation which could affect cytokine concentration in serum or aqueous humor (ah)

Keywords: type 2 diabetes mellitus cataract cytokines chemokines aqueous humor
children's activity and nutrition iii

Conditions: Cardiovascular Diseases; Hypertension; Coronary Disease

Summary: to track blood pressure from childhood through adolescence.

background: children's activity and nutrition iii was originally part of the institute-initiated studies of children's activity and nutrition (scan), first funded in 1985. children's activity and nutrition iii was renewed in 1992 as a stand-alone project with a focus on assessment of the development of hemodynamic mechanisms responsible for blood pressure (bp) control within the context of ethnicity and family history of early myocardial infarction (mi), defined as having a parent or grandparent with an mi at less than 55 years of age and a family history. blacks have a higher mortality rate through middle adulthood than whites from coronary heart disease (chd), the leading causes of death in the united states. blacks have been found to exhibit greater cardiovascular (cv) response to stress (i.e., reactivity), a potential risk factor for chd, as have individuals with a family history. . although chd has its pathobiologic origins in childhood, little longitudinal reactivity research has been conducted in youth, especially from childhood through late adolescence. design narrative: the study followed a multiethnic sample of 250 13 to 14 year olds for an additional 5 years to determine: 1) whether blood pressure (bp) reactivity during childhood predicted changes in resting bp, left ventricular mass and concentric remodeling, carotid artery wall elasticity and endothelial dependent arterial dilation up to 11 years later after controlling for other expected predictors (i.e., age, gender, ethnicity, resting bp, adiposity, ambulatory bp); 2) the influence of ethnicity, family history and a select group of moderator variables (i.e., environmental stress, anger and john henryism coping styles, aerobic fitness on youth's cardiovascular (cv) reactivity; and 3) the stability of cv reactivity and a 24- hour ambulatory bp from childhood through late adolescence. the long- term objectives were to provide a better understanding of the development of cv reactivity in youth and its influence upon early pathobiologic markers of coronary heart disease prior to overt manifestation of disease.

Eligibility criteria:
no eligibility criteria
real world study of first line crizotinib for alk rearranged non-squamous non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this study aims to explore the efficacy and safety of crizotinib as a first-line therapy for advanced non-squamous non-small cell lung cancer with alk-positive mutations in the real world.

according to the study of p11014 and p1029, crizotinib is a first-line therapy for advanced non squamous non small cell lung cancer with positive alk rearrangement.this study aims to explore the efficacy and safety of clozotinib as a first-line therapy for advanced non-squamous non-small cell lung cancer with alk-positive mutations in the real world. among them, alk positive was based on ngs test results, exploring the new drug resistance mechanism of alk under clozotinib treatment mode and consistency between plasma and tissue detection driving genes, and finally assessing the role of plasma dynamic detection driving gene mutation spectrum in predicting disease progression risk. a retrospective study of 120 patients with advanced nsclc using clozotinib alk positive mutation was conducted to observe the efficacy and safety of clozotinib regimen in the real world.

Eligibility criteria:
inclusion criteria: * ≥18，pathologically proven alk positive mutation in advanced non squamous non small cell lung cancer * alk rearrangement detection method is ngs and ventana * primary treatment of first diagnosis * the treatment was crizotinib 250mg po bid exclusion criteria * patients received antitumor treatment before * patients with contraindication of chemotherapy * pregnant or breast feeding women

Keywords: non-small cell lung cancer alk rearranged crizotinib